Compare AU
Compare PAVE vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are PAVE and CURE. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
PAVE | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 5 | 80 |
Median incremental investment | $1,493.50 | $620.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $1,954.88 | $1,325.53 |
Average age group | > 35 | > 35 |
Key Summary
PAVE | CURE | |
|---|---|---|
Strategy | PAVE.AX was created on 2024-06-03 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Indxx U.S. Infrastructure Development Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Global X Us Infrastructure Development ETF (100 %) | Neurocrine Biosciences Inc (2.75 %) Alnylam Pharmaceuticals Inc (2.52 %) Insmed Inc (2.46 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.47 % | 0.45 % |
Key Summary
PAVE | CURE | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | Indxx U.S. Infrastructure Development Index | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.47 % | 0.45 % |
Price | $11.84 | $50.44 |
Size | $11.669 million | $34.226 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | - % | 4.24 % |
Market | ASX | ASX |
First listed date | 04/06/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
PAVE | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 5 | 80 |
Median incremental investment | $1,493.50 | $620.50 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $1,954.88 | $1,325.53 |
Average age group | > 35 | > 35 |
Pros and Cons
PAVE | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
PAVE | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |